Thursday, 5 November 2026European Markets

PETRONOR E&P Stock Impressive Jump 18% So Far On Wednesday, Outperforms Market

Loading stream...

(VIANEWS) - Shares of PETRONOR E&P (Oslo Børs Benchmark Index_GI: PNOR.OL) rose by a staggering 18.89% to kr8.23 at 11:38 EST on Wednesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 0.32% to kr1,189.99, following the last session's downward trend. This seems, as yet, a somewhat positive trend exchanging session today.

PETRONOR E&P's last close was kr6.93, 44.43% below its 52-week high of kr12.47.

About PETRONOR E&P

PetroNor E&P ASA operates as an independent oil and gas exploration and production company in West Africa. It holds exploration and production assets in offshore West Africa countries, which includes the PNGF Sud licenses in Congo Brazzaville, the A4 license in The Gambia, the Sinapa (Block 2) and Esperança (Blocks 4A and 5A) licenses in Guinea-Bissau, the Rufisque Offshore Profond and Senegal Offshore Sud Profond in Senegal, and OML-113 in Nigeria. The company was founded in 2017 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PETRONOR E&P has a trailing twelve months EPS of kr2.1.

PE Ratio

PETRONOR E&P has a trailing twelve months price to earnings ratio of 3.92. Meaning, the purchaser of the share is investing kr3.92 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 39.01%.

More news about PETRONOR E&P (PNOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com